Login
Companies $TNYA
$0.34 +$0.01 (1.92%) After hours
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc.

tenayatherapeutics.com

What Do They Do?

Develops gene therapies and small-molecule drug candidates aimed at the underlying causes of heart disease for patients with genetic heart conditions and other cardiac, muscular and metabolic diseases.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
Net income
▲ +7% (Loss)
vs −$20.3M in Q3 FY2025
  • Jul 2, 2026 Tenaya ended the lease for its manufacturing facility The company plans to transfer its AAV manufacturing process to a contract manufacturer.
  • Jun 29, 2026 Tenaya appointed Eric Hyllengren as chief financial officer He became CFO on July 13, 2026.

Narrower platform focus The older report described separate gene therapy, cellular regeneration and precision medicine platforms, including a cardiac regeneration program. The latest report focuses its clinical-stage pipeline on gene therapies and a small-molecule candidate, and describes its discovery capabilities across modalities.

Manufacturing approach The older report described internal AAV manufacturing capabilities and a manufacturing center. The latest report describes process and analytical development capabilities that supported clinical trial material production and development of know-how to manage later manufacturing; a later filing says the company plans to transfer its process to a contract manufacturer.

Who Do They Compete With?

Competes with Bristol Myers Squibb, Cytokinetics, Edgewise Therapeutics, Lexicon Pharmaceutical, Imbria Pharmaceutical, Novartis, Eli Lilly, Boehringer Ingleheim, Astra Zeneca, Italfarmaco, Catalyst Pharmaceuticals, Santhera Pharmaceutical, PTC Therapeutics, Sarepta Therapeutics, NS Pharma, Capricor Therapeutics, Avidity Bioscience, Rocket Pharmaceutical, and Lexeo Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support